Ascendis Pharma A/S - Ordinary Share (NQ:ASND)
Price and Volume
Detailed Quote| Volume | 31,438 |
| Open | 227.13 |
| Bid (Size) | 227.30 (200) |
| Ask (Size) | 227.97 (100) |
| Prev. Close | 227.31 |
| Today's Range | 226.00 - 227.96 |
| 52wk Range | 186.05 - 282.15 |
| Shares Outstanding | 57,152,295 |
| Dividend Yield | N/A |
Top News
More NewsPerformance
More News
Read More
Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript ↗
August 20, 2026
Ascendis Pharma A/S Q2 Earnings Call Highlights ↗
August 13, 2026
Ascendis (ASND) Q1 2026 Earnings Call Transcript ↗
May 08, 2026
Ascendis (ASND) Q4 2025 Earnings Call Transcript ↗
February 23, 2026
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript ↗
February 11, 2026
Frequently Asked Questions
Is Ascendis Pharma A/S - Ordinary Share publicly traded?
Yes, Ascendis Pharma A/S - Ordinary Share is publicly traded.
What exchange does Ascendis Pharma A/S - Ordinary Share trade on?
Ascendis Pharma A/S - Ordinary Share trades on the Nasdaq Stock Market
What is the ticker symbol for Ascendis Pharma A/S - Ordinary Share?
The ticker symbol for Ascendis Pharma A/S - Ordinary Share is ASND on the Nasdaq Stock Market
What is the current price of Ascendis Pharma A/S - Ordinary Share?
The current price of Ascendis Pharma A/S - Ordinary Share is 227.63
When was Ascendis Pharma A/S - Ordinary Share last traded?
The last trade of Ascendis Pharma A/S - Ordinary Share was at 10/02/26 09:45 AM ET
What is the market capitalization of Ascendis Pharma A/S - Ordinary Share?
The market capitalization of Ascendis Pharma A/S - Ordinary Share is 13.01B
How many shares of Ascendis Pharma A/S - Ordinary Share are outstanding?
Ascendis Pharma A/S - Ordinary Share has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.